NCT07434635

Brief Summary

The study will evaluate whether atropine eyedrops are beneficial when used after certain eye surgeries.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
62

participants targeted

Target at P25-P50 for phase_4

Timeline
30mo left

Started Mar 2026

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress14%
Mar 2026Feb 2029

First Submitted

Initial submission to the registry

February 5, 2026

Completed
20 days until next milestone

First Posted

Study publicly available on registry

February 25, 2026

Completed
13 days until next milestone

Study Start

First participant enrolled

March 10, 2026

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2028

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2029

Last Updated

July 31, 2026

Status Verified

July 1, 2026

Enrollment Period

1.9 years

First QC Date

February 5, 2026

Last Update Submit

July 29, 2026

Conditions

Eye Disorders

Keywords

atropineeye surgery

Outcome Measures

Primary Outcomes (1)

  • Pain score on the Visual Analog Scale (VAS)

    Whether atropine use impacts post-operative pain score on the standard Visual Analog Scale (VAS)

    1 month

Secondary Outcomes (5)

  • Anterior chamber inflammation (aqueous cell and flare)

    1 month

  • Cystoid macular edema detected by optical coherence tomography

    1 month

  • Time to visual recovery

    1 month

  • Intraocular pressure

    1 month

  • Posterior synechiae formation

    1 month

Study Arms (2)

Control

NO INTERVENTION

No atropine

Experimental

EXPERIMENTAL

Participant uses atropine eyedrops

Drug: Atropine 1%

Interventions

Atropine 1%DRUG

Subtraction of atropine eyedrops from post-operative treatment regimen

Also known as: Atropine
Experimental

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patient undergoing vitrectomy surgery
  • able to give informed consent

You may not qualify if:

  • post-operative eyedrop regimens that include topical non steroidal anti-inflammatory medications
  • subjects with altered post-operative eyedrop schedule for enhanced inflammation control
  • documented allergy to atropine

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of California, San Francisco

San Francisco, California, 94143, United States

RECRUITING

MeSH Terms

Conditions

Eye Diseases

Interventions

Atropine

Intervention Hierarchy (Ancestors)

Atropine DerivativesTropanesAzabicyclo CompoundsAza CompoundsOrganic ChemicalsBelladonna AlkaloidsSolanaceous AlkaloidsAlkaloidsHeterocyclic CompoundsBridged Bicyclo Compounds, HeterocyclicHeterocyclic Compounds, Bridged-Ring

Study Officials

  • Jay Stewart, MD

    University of California, San Francisco

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jay Stewart, MD

CONTACT

415-353-9635eyestudy@ucsf.edu

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 5, 2026

First Posted

February 25, 2026

Study Start

March 10, 2026

Primary Completion (Estimated)

February 1, 2028

Study Completion (Estimated)

February 1, 2029

Last Updated

July 31, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share

Locations

US(1)